Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Licochalcone E is a natural retrochalcone flavonoid isolated from the roots of Glycyrrhiza species (licorice), such as Glycyrrhiza inflata and Glycyrrhiza uralensis. It exhibits a wide range of pharmacological properties, including anti-inflammatory, anti-cancer, anti-diabetic, and anti-obesity activities. Mechanistically, licochalcone E acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ) and an agonist of liver X receptor beta (LXRβ), while antagonizing liver X receptor alpha (LXRα). It also activates the Nrf2/ARE antioxidant pathway and inhibits the activation of NF-κB and AP-1 by suppressing AKT and MAPK signaling pathways. In preclinical models, licochalcone E has demonstrated the ability to inhibit solid tumor growth and metastasis in breast cancer, improve insulin sensitivity, and ameliorate hepatic steatosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on licochalcone E.